Profile data is unavailable for this security.
About the company
Chengdu Olymvax Biopharmaceuticals Inc is a China-based biopharmaceutical company mainly engaged in the research, development, production and sales of human vaccines. The Company's products mainly include adsorbed tetanus vaccine, Hib conjugate vaccine and tetanus toxoid concentrate stock solution. The Company's main customers are center for disease control and prevention (CDC) customers.
- Revenue in CNY (TTM)500.05m
- Net income in CNY-12.30m
- Incorporated2009
- Employees471.00
- LocationChengdu Olymvax Biopharmaceuticals IncNo. 99 Tianxin Road, High-tech ZoneCHENGDU 611731ChinaCHN
- Phone+86 2 869361198
- Fax+86 2 869361100
- Websitehttps://www.olymvax.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jiangsu Bioperfectus Technologies Co Ltd | 400.25m | -314.32m | 3.74bn | 684.00 | -- | 1.09 | -- | 9.34 | -5.36 | -5.36 | 6.83 | 58.77 | 0.0915 | 0.8592 | 1.57 | 585,153.50 | -7.19 | 25.41 | -8.36 | 31.26 | 63.20 | 63.37 | -78.53 | 32.86 | 6.05 | -- | 0.086 | 30.54 | -92.72 | 11.81 | -120.45 | -- | 2.43 | -- |
| Jinyao Pharmaceutical Co Ltd | 3.66bn | 107.59m | 3.77bn | 2.68k | 35.05 | 1.25 | -- | 1.03 | 0.0984 | 0.0984 | 3.35 | 2.76 | 0.5738 | 2.28 | 9.37 | 1,365,219.00 | 2.33 | 1.91 | 4.17 | 3.40 | 42.61 | 46.33 | 4.06 | 3.31 | 0.7584 | 27.18 | 0.2064 | 44.40 | 2.55 | 9.28 | 230.60 | -4.22 | -9.58 | 9.21 |
| Shanghai OPM Biosciences Co Ltd | 254.91m | 49.43m | 3.78bn | 285.00 | 76.59 | 1.75 | -- | 14.84 | 0.4303 | 0.4303 | 2.22 | 18.80 | 0.1095 | 2.07 | 2.54 | 894,431.90 | 2.09 | 4.34 | 2.16 | 4.65 | 58.86 | 58.31 | 19.06 | 23.40 | 19.91 | -- | 0.0315 | 45.38 | -17.41 | 48.34 | -48.72 | -- | 6.09 | -- |
| Hangzhou Alltest Biotech Co Ltd | 718.48m | 184.83m | 3.78bn | 1.09k | 20.50 | 0.9656 | -- | 5.27 | 2.33 | 2.33 | 9.02 | 49.43 | 0.165 | 2.13 | 6.17 | 657,349.00 | 4.24 | 23.35 | 4.57 | 26.83 | 46.83 | 58.34 | 25.69 | 39.07 | 10.16 | -- | 0.0056 | 29.79 | -77.73 | 32.59 | -84.75 | 26.19 | 72.77 | -- |
| Chengdu Olymvax Biopharmaceuticals Inc | 500.05m | -12.30m | 3.84bn | 471.00 | -- | 4.28 | -- | 7.68 | -0.0303 | -0.0303 | 1.23 | 2.21 | 0.3338 | 0.4197 | 1.08 | 1,061,669.00 | -1.22 | 3.17 | -1.70 | 4.68 | 93.29 | 93.00 | -3.64 | 7.44 | 1.92 | -3.90 | 0.2505 | 9.82 | -9.38 | 45.40 | -33.94 | -- | 56.47 | -- |
| Hainan Huluwa Pharmaceutical Grop Co Ltd | 1.81bn | 94.97m | 3.87bn | 2.47k | 40.74 | 3.37 | -- | 2.14 | 0.2374 | 0.2374 | 4.52 | 2.87 | 0.6721 | 2.88 | 3.81 | 732,708.90 | 3.80 | 5.81 | 6.29 | 9.78 | 50.33 | 58.01 | 5.66 | 7.03 | 0.8245 | 7.04 | 0.5246 | 21.74 | 25.75 | 14.13 | 24.29 | 1.16 | 46.37 | -- |
| Getein Biotech Inc | 1.31bn | 244.26m | 3.94bn | 2.14k | 16.11 | 1.49 | -- | 3.01 | 0.4816 | 0.4816 | 2.58 | 5.22 | 0.3502 | 1.61 | 2.77 | 611,337.70 | 6.63 | 13.25 | 9.24 | 18.45 | 66.13 | 65.57 | 18.92 | 28.13 | 1.97 | -- | 0.1857 | 29.88 | -24.85 | 14.81 | -43.92 | 2.31 | 18.44 | 6.00 |
Data as of Jun 26 2024. Currency figures normalised to Chengdu Olymvax Biopharmaceuticals Inc's reporting currency: Chinese Yuan Renminbi CNY
8.93%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| GF Fund Management Co., Ltd.as of 31 Dec 2023 | 17.30m | 6.00% |
| Orient Securities Asset Management Co. Ltd.as of 31 Dec 2023 | 2.62m | 0.91% |
| Fullgoal Fund Management Co., Ltd.as of 31 Dec 2023 | 2.54m | 0.88% |
| Bank of Communications Schroder Fund Management Co., Ltd.as of 31 Dec 2023 | 653.72k | 0.23% |
| UBS SDIC Fund Management Co., Ltd.as of 30 Jun 2023 | 586.82k | 0.20% |
| Hongde Fund Management Co., Ltd.as of 31 Dec 2023 | 551.12k | 0.19% |
| Zhong Ou Asset Management Co., Ltdas of 31 Dec 2023 | 467.71k | 0.16% |
| Truvalue Asset Management Co. Ltd.as of 31 Dec 2023 | 409.88k | 0.14% |
| China Asset Management Co., Ltd.as of 31 Dec 2023 | 327.13k | 0.11% |
| Harvest Fund Management Co., Ltd.as of 31 Dec 2023 | 283.64k | 0.10% |
More ▼
Data from 30 Jun 2023 - 29 Apr 2024Source: FactSet Research Systems Inc.
